One only needs to look at Europe to see the future, says a pharmacy expert, who sees the US payer landscape moving to greater biosimilar adoption in 2020.
Zarxio, a filgrastim biosimilar, arrived on the US market in September 2015. An infliximab biosimilar followed in 2016. The United States now has 26 approved biosimilars, of which 17 are on the market and a few dozen more are in the pipeline.
There is a lot of experience with biosimilars in this country already, and as a panel of pharmacy experts stated recently, the market share enjoyed by these products is growing.
“Believe it or not, the market share is about 9% for the entire country. Whereas if you look in Europe, they actually have a market share over 70%,” said Bhavesh Shah, RPh, BCOP, in a Pharmacy Times®—hosted discussion that compared the US market with the more mature European market.
Here vs There
“There’s definitely a better adoption of biosimilars in Europe across the landscape of biosimilars,” said Shah, senior director of specialty and hematology/oncology pharmacy at Boston Medical Center Health System, in Massachusetts.
A key difference is the level of government intervention in the way the markets operate, he noted.
“A lot of their decisions are made at the government level, so it’s much easier when the government says that they’re going to switch everybody in 1 day. In Norway, they basically switched patients from one biosimilar to another multiple times in a year because of contracts. If they have a better contract with a manufacturer [several months later], they’ll actually switch everybody to that biosimilar,” Shah said.
Payers also have more control over the types of agents that are prescribed, he added. In the United States, Kaiser Permanente has had a high degree of success switching patients to biosimilars, and this is a pattern that likely will be continued across the payer community in 2020, Shah said.
For the full story, visit Pharmacy Times®.
Pharmacy Times® and The Center for Biosimilars® share the same parent company, MJH Life Sciences™, the largest privately held, independent, full-service medical media company in North America, dedicated to delivering trusted health care news across multiple channel.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Patients With IBD Maintain Therapy 2 Years Post Switching to Infliximab Biosimilar
March 23rd 2025People with inflammatory bowel disease (IBD) who switched to the infliximab biosimilar CT-P13 had higher treatment persistence (84% and 91%) than those new to infliximab (66% and 53%), with no new safety concerns.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
How Vertical Integration Drives Innovation and Access in Biosimilars
December 27th 2024Elie Bahou, PharmD, highlights how vertical integration in the biosimilar industry streamlines costs, improves supply reliability, accelerates market adoption, and enhances patient access, while emphasizing the value of collaboration, quality control, and value-based contracts for sustainable health care delivery.
Empowering Vulnerable Populations: The Path to Equitable Biologic Therapy Access
December 22nd 2024Elie Bahou, PharmD, senior vice president and system chief pharmacy officer at Providence, discusses strategies to improve equitable access to biologic therapies, including tiered formularies, income-based cost sharing, patient assistance programs, and fostering payer partnerships.